|
1
|
Huober J, Fasching PA, Hanusch C, Rezai M,
Eidtmann H, et al: Neoadjuvant chemotherapy with paclitaxel and
everolimus in breast cancer patients with non-responsive tumours to
epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the
randomised GeparQuinto study (GBG 44). Eur J Cancer. 49:2284–2293.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
van der Burg ME, Vergote I, Onstenk W,
Boere IA, Leunen K, et al: Long-term results of weekly paclitaxel
carboplatin induction therapy: an effective and well-tolerated
treatment in patients with platinum-resistant ovarian cancer. Eur J
Cancer. 49:1254–1263. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Leong SS, Wee J, Rajan S, Toh CK, Lim WT,
et al: Triplet combination of gemcitabine, paclitaxel, and
carboplatin followed by maintenance 5-fluorouracil and folinic acid
in patients with metastatic nasopharyngeal carcinoma. Cancer.
113:1332–1337. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yusuf RZ, Duan Z, Lamendola DE, Penson RT
and Seiden MV: Paclitaxel resistance: molecular mechanisms and
pharmacologic manipulation. Curr Cancer Drug Targets. 3:1–19. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fåhraeus R, Fu HL, Ernberg I, Finke J,
Rowe M, et al: Expression of Epstein-Barr virus-encoded proteins in
nasopharyngeal carcinoma. Int J Cancer. 42:329–338. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen C, Wang FH, An X, Luo HY, Wang ZQ, et
al: Triplet combination with paclitaxel, cisplatin and 5-FU is
effective in metastatic and/or recurrent nasopharyngeal carcinoma.
Cancer Chemother Pharmacol. 71:371–378. 2013. View Article : Google Scholar
|
|
7
|
Pasquale EB: Eph receptor signalling casts
a wide net on cell behaviour. Nat Rev Mol Cell Biol. 6:462–475.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sulman EP, Tang XX, Allen C, Biegel JA,
Pleasure DE, et al: ECK, a human EPH-related gene, maps to 1p36.1,
a common region of alteration in human cancers. Genomics.
40:371–374. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu Y, Zhang X, Qiu Y, Huang D, Zhang S,
et al: Clinical significance of EphA2 expression in squamous-cell
carcinoma of the head and neck. J Cancer Res Clin Oncol.
137:761–769. 2011. View Article : Google Scholar
|
|
10
|
Kinch MS, Moore MB and Harpole DH Jr:
Predictive value of the EphA2 receptor tyrosine kinase in lung
cancer recurrence and survival. Clin Cancer Res. 9:613–618.
2003.PubMed/NCBI
|
|
11
|
Mudali SV, Fu B, Lakkur SS, Luo M,
Embuscado EE and Iacobuzio-Donahue CA: Patterns of EphA2 protein
expression in primary and metastatic pancreatic carcinoma and
correlation with genetic status. Clin Exp Metastasis. 23:357–365.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abraham S, Knapp DW, Cheng L, Snyder PW,
Mittal SK, et al: Expression of EphA2 and Ephrin A-1 in carcinoma
of the urinary bladder. Clin Cancer Res. 12:353–360. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zelinski DP, Zantek ND, Stewart JC,
Irizarry AR and Kinch MS: EphA2 overexpression causes tumorigenesis
of mammary epithelial cells. Cancer Res. 61:2301–2306.
2001.PubMed/NCBI
|
|
14
|
Herrem CJ, Tatsumi T, Olson KS, Shirai K,
Finke JH, et al: Expression of EphA2 is prognostic of disease-free
interval and overall survival in surgically treated patients with
renal cell carcinoma. Clin Cancer Res. 11:226–231. 2005.PubMed/NCBI
|
|
15
|
Brantley-Sieders DM, Zhuang G, Hicks D,
Fang WB, Hwang Y, et al: The receptor tyrosine kinase EphA2
promotes mammary adenocarcinoma tumorigenesis and metastatic
progression in mice by amplifying ErbB2 signaling. J Clin Invest.
118:64–78. 2008. View
Article : Google Scholar
|
|
16
|
Lin YG, Han LY, Kamat AA, Merritt WM,
Landen CN, et al: EphA2 overexpression is associated with
angiogenesis in ovarian cancer. Cancer. 109:332–340. 2007.
View Article : Google Scholar
|
|
17
|
Lu C, Shahzad MM, Wang H, Landen CN, Kim
SW, et al: EphA2 overexpression promotes ovarian cancer growth.
Cancer Biol Ther. 7:1098–1103. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Duxbury MS, Ito H, Zinner MJ, Ashley SW
and Whang EE: EphA2: a determinant of malignant cellular behavior
and a potential therapeutic target in pancreatic adenocarcinoma.
Oncogene. 23:1448–1456. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Landen CN Jr, Chavez-Reyes A, Bucana C,
Schmandt R, Deavers MT, et al: Therapeutic EphA2 gene targeting in
vivo using neutral liposomal small interfering RNA delivery. Cancer
Res. 65:6910–6918. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shen H, Rodriguez-Aguayo C, Xu R,
Gonzalez-Villasana V, Mai J, et al: Enhancing chemotherapy response
with sustained EphA2 silencing using multistage vector delivery.
Clin Cancer Res. 19:1806–1815. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang S, Placzek WJ, Stebbins JL, Mitra S,
Noberini R, et al: Novel targeted system to deliver
chemotherapeutic drugs to EphA2-expressing cancer cells. J Med
Chem. 55:2427–2436. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang S, Noberini R, Stebbins JL, Das S,
Zhang Z, et al: Targeted delivery of paclitaxel to EphA2-expressing
cancer cells. Clin Cancer Res. 19:128–137. 2013. View Article : Google Scholar :
|
|
23
|
Tan P, Liu Y, Yu C, Su Z, Li G, et al:
EphA2 silencing in nasopharyngeal carcinoma leads to decreased
proliferation, invasion and increased sensitization to paclitaxel.
Oncol Lett. 4:429–434. 2012.
|
|
24
|
Liu Y, Yu C, Qiu Y, Huang D, Zhou X, et
al: Downregulation of EphA2 expression suppresses the growth and
metastasis in squamous-cell carcinoma of the head and neck in vitro
and in vivo. J Cancer Res Clin Oncol. 138:195–202. 2012. View Article : Google Scholar
|
|
25
|
Parri M, Taddei ML, Bianchini F, Calorini
L and Chiarugi P: EphA2 reexpression prompts invasion of melanoma
cells shifting from mesenchymal to amoeboid-like motility style.
Cancer Res. 69:2072–2081. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Landen CN Jr, Lu C, Han LY, Coffman KT,
Bruckheimer E, et al: Efficacy and antivascular effects of EphA2
reduction with an agonistic antibody in ovarian cancer. J Natl
Cancer Inst. 98:1558–1570. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yared JA and Tkaczuk KH: Update on taxane
development: new analogs and new formulations. Drug Des Devel Ther.
6:371–384. 2012.PubMed/NCBI
|
|
28
|
He K, Xu T, Xu Y, Ring A, Kahn M and
Goldkorn A: Cancer cells acquire a drug resistant, highly
tumorigenic, cancer stem-like phenotype through modulation of the
PI3K/Akt/β-catenin/CBP pathway. Int J Cancer. 134:43–54. 2014.
View Article : Google Scholar
|
|
29
|
Wang Y, Chen L, Huang G, He D, He J, et
al: Klotho sensitizes human lung cancer cell line to cisplatin via
PI3k/Akt pathway. PLoS One. 8:e573912013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xiu P, Dong X, Dong X, Xu Z, Zhu H, Liu F,
et al: Secretory clusterin contributes to oxaliplatin resistance by
activating Akt pathway in hepatocellular carcinoma. Cancer Sci.
104:375–382. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang YI, Lee KT, Park HJ, Kim TJ, Choi YS,
et al: Tectorigenin sensitizes paclitaxel-resistant human ovarian
cancer cells through downregulation of the Akt and NFκB pathway.
Carcinogenesis. 33:2488–2498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim TR, Cho EW, Paik SG and Kim IG:
Hypoxia-induced SM22α in A549 cells activates the IGF1R/PI3K/Akt
pathway, conferring cellular resistance against chemo- and
radiation therapy. FEBS Lett. 586:303–309. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wykosky J and Debinski W: The EphA2
receptor and ephrinA1 ligand in solid tumors: function and
therapeutic targeting. Mol Cancer Res. 6:1795–1806. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gréen H, Söderkvist P, Rosenberg P,
Horvath G and Peterson C: mdr-1 single nucleotide polymorphisms in
ovarian cancer tissue: G2677T/A correlates with response to
paclitaxel chemotherapy. Clin Cancer Res. 12:854–859. 2006.
View Article : Google Scholar : PubMed/NCBI
|
